Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Davita Healthcare Partners Inc (DVA)

Davita Healthcare Partners Inc (DVA)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 10,178,623
  • Shares Outstanding, K 125,600
  • Annual Sales, $ 11,388 M
  • Annual Income, $ 810,980 K
  • 60-Month Beta 1.70
  • Price/Sales 0.89
  • Price/Cash Flow 7.19
  • Price/Book 4.48

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 8 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/20
See More
  • Average Estimate 1.47
  • Number of Estimates 7
  • High Estimate 1.56
  • Low Estimate 1.42
  • Prior Year 0.91
  • Growth Rate Est. (year over year) +61.54%

Price Performance

See More
Period Period Low Period High Performance
1-Month
77.96 +3.13%
on 02/27/20
90.15 -10.82%
on 02/12/20
-1.63 (-1.99%)
since 01/27/20
3-Month
70.66 +13.78%
on 12/03/19
90.15 -10.82%
on 02/12/20
+7.71 (+10.61%)
since 11/27/19
52-Week
43.40 +85.25%
on 05/31/19
90.15 -10.82%
on 02/12/20
+23.48 (+41.25%)
since 02/27/19

Most Recent Stories

More News
Davita Inc Up 40.2% Since SmarTrend Uptrend Call (DVA)

SmarTrend identified an Uptrend for Davita Inc (NYSE:DVA) on October 18th, 2019 at $57.79. In approximately 4 months, Davita Inc has returned 40.23% as of today's recent price of $81.04.

DVA : 79.39 (-2.04%)
Has DaVita (DVA) Outpaced Other Medical Stocks This Year?

Is (DVA) Outperforming Other Medical Stocks This Year?

DVA : 79.39 (-2.04%)
Telehealth App Helps Connect Dialysis Patients Treating at Home

DaVita Kidney Care achieved another industry first by incorporating a secure telehealth platform, DaVita Care Connect(TM), into its home dialysis program. DaVita Care Connect(TM) is one of many connective...

DVA : 79.39 (-2.04%)
Why DaVita (DVA) Could Be an Impressive Growth Stock

If you are looking for a fast-growing stock that is still seeing plenty of opportunities on the horizon, make sure to consider DaVita (DVA).

DVA : 79.39 (-2.04%)
After Yesterday's Decline of 1.26%, Davita Inc Offers Investors Better Value

Davita Inc (NYSE:DVA) traded in a range yesterday that spanned from a low of $84.62 to a high of $85.47. Yesterday, the shares fell 1.3%, which took the trading range below the 3-day low of $84.78 on...

DVA : 79.39 (-2.04%)
SmarTrend Watching for Potential Rebound in Shares of Davita Inc After 1.26% Loss

Davita Inc (NYSE:DVA) traded in a range yesterday that spanned from a low of $84.62 to a high of $85.47. Yesterday, the shares fell 1.3%, which took the trading range below the 3-day low of $84.78 on...

DVA : 79.39 (-2.04%)
Why DaVita (DVA) Could Be Positioned for a Surge

DaVita (DVA) is seeing positive earnings estimate revisions, suggesting that it could be a solid choice for investors.

DVA : 79.39 (-2.04%)
DaVita Names Kenny Gardner Chief People Officer

DaVita Kidney Care recently announced Kenny Gardner as its new chief people officer (CPO). Gardner has been with DaVita for nearly a decade and most recently served the company as a group vice president...

DVA : 79.39 (-2.04%)
Zacks.com featured highlights include: Tempur Sealy International, Twin River Worldwide, Rite Aid, DaVita and United Therapeutics

Zacks.com featured highlights include: Tempur Sealy International, Twin River Worldwide, Rite Aid, DaVita and United Therapeutics

RAD : 13.48 (+3.45%)
DVA : 79.39 (-2.04%)
UTHR : 100.91 (-4.63%)
TPX : 77.93 (-2.56%)
TRWH : 26.67 (-1.91%)
Top Ranked Growth Stocks to Buy for February 19th

Top Ranked Growth Stocks to Buy for February 19th

MITK : 8.88 (-2.84%)
LCII : 100.13 (-4.68%)
IBP : 69.53 (-0.20%)
DVA : 79.39 (-2.04%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 80% Buy with a Weakening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Trade DVA with:

Business Summary

DaVita Inc. is the parent company of DaVita Kidney Care and HealthCare Partners. DaVita Kidney Care is a provider of kidney care, delivering dialysis services for chronic kidney failure and end stage renal disease primarily in the United States. HealthCare Partners manages and operates medical groups...

See More

Key Turning Points

2nd Resistance Point 83.35
1st Resistance Point 82.20
Last Price 79.39
1st Support Level 80.21
2nd Support Level 79.37

See More

52-Week High 90.15
Last Price 79.39
Fibonacci 61.8% 72.29
Fibonacci 50% 66.78
Fibonacci 38.2% 61.26
52-Week Low 43.40

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar